

Maryam B Lustberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1705518/maryam-b-lustberg-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

3,737
citations

26
h-index

58
g-index

137
ext. papers

5,046
ext. citations

4.6
avg, IF

5.52
L-index

#	Paper	IF	Citations
123	Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy.. <i>Current Treatment Options in Oncology</i> , 2022 , 23, 29	5.4	2
122	Abstract P4-10-09: Patient-centered dosing: Oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). <i>Cancer Research</i> , 2022 , 82, P4-10-09-P4-10-09	10.1	0
121	Activity of Estrogen Receptor Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.. <i>Frontiers in Oncology</i> , 2022 , 12, 857590	5.3	1
120	Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-10	7.1	0
119	Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapy. <i>Nutritional Neuroscience</i> , 2021 , 1-9	3.6	1
118	Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. <i>The Journal of Breast Health</i> , 2021 , 17, 371-377	1.5	0
117	Readdressing the Needs of Cancer Survivors During COVID-19: A Path Forward. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 955-961	9.7	4
116	Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. <i>Quality of Life Research</i> , 2021 , 30, 3241-3254	3.7	0
115	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 249-258	4.4	7
114	Supportive Care: Low Cost, High Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-11	7.1	0
113	A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. <i>Journal of Oncology</i> , 2021 , 2021, 9965583	4.5	2
112	Introduction to special section: Living with Incurable Cancer: Addressing Gaps in Cancer Survivorship. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 367-369	5.1	4
111	Erythrocyte Long-Chain n-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer. <i>Journal of Nutrition</i> , 2021 , 151, 2125-2133	4.1	1
110	The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients. <i>Current Developments in Nutrition</i> , 2021 , 5, 70-70	0.4	78
109	Primary care physician's confidence and coordination regarding the survivorship care for older breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021 , 29, 223-230	3.9	3
108	Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 155-161	3.3	12
107	Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021 , 10, 109-114	2.2	2

106	Pilot study of fractional CO laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. <i>Maturitas</i> , 2021 , 144, 37-44	5	8
105	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 135-148	3.5	16
104	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. <i>Supportive Care in Cancer</i> , 2021 , 29, 2821-2840	3.9	15
103	Worry and rumination in breast cancer patients: perseveration worsens self-rated health. <i>Journal of Behavioral Medicine</i> , 2021 , 44, 253-259	3.6	9
102	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
101	The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100614	3.3	2
100	Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. <i>Menopause</i> , 2021 , 28, 642-649	2.5	5
99	Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. <i>Cancers</i> , 2021 , 13,	6.6	11
98	Effects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic review. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	3
97	Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 183-188	4.4	1
96	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021 , 99, 102241	14.4	7
95	Dissemination of cancer survivorship care plans: who is being left out?. <i>Supportive Care in Cancer</i> , 2021 , 29, 4295-4302	3.9	4
94	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. <i>BMC Cancer</i> , 2020 , 20, 445	4.8	3
93	Advances and future directions in the use of mobile health in supportive cancer care: proceedings of the 2019 MASCC Annual Meeting symposium. <i>Supportive Care in Cancer</i> , 2020 , 28, 4059-4067	3.9	11
92	TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature. <i>Frontiers in Endocrinology</i> , 2020 , 11, 228	5.7	7
91	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	14.1	880
90	Metastatic breast cancer patient perceptions of somatic tumor genomic testing. <i>BMC Cancer</i> , 2020 , 20, 389	4.8	2
89	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 620-628	15.1	21

88	Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. <i>World Journal of Surgical Oncology</i> , 2020 , 18, 11	3.4	7
87	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1400-1410	4.3	12
86	Role of transporters in toxicity induced by anticancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 493-506	5.5	6
85	Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. <i>Blood</i> , 2020 , 136, 17-18	2.2	1
84	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4601-4606	15.9	22
83	Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls. <i>The Journal of Breast Health</i> , 2020 , 16, 201-207	1.5	1
82	Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020 , 28, 3669-3677	3.9	15
81	SCHEDULING DELAYED TREATMENT AND SURGERIES POST-PANDEMIC: A STAKEHOLDER ANALYSIS. <i>Proceedings of the International Symposium of Human Factors and Ergonomics in Healthcare</i> , 2020 , 9, 10-14	0.5	1
80	A Human Factors Perspective to Characterize Treatment and Surgery During the COVID-19 Pandemic. <i>Proceedings of the International Symposium of Human Factors and Ergonomics in Healthcare</i> , 2020 , 9, 1-5	0.5	1
79	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3325-3348	2.2	168
78	The microbiota-gut-brain axis: An emerging therapeutic target in chemotherapy-induced cognitive impairment. <i>Neuroscience and Biobehavioral Reviews</i> , 2020 , 116, 470-479	9	7
77	Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 1-9	4.4	8
76	Multidisciplinary patient-centered management of brain metastases and future directions. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa034	0.9	10
75	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020 , 1	2.9	4
74	Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 1865-1876	6.4	7
73	Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, 33-40	3	21
72	Primary care physicians' perspectives of the survivorship care for older breast cancer survivors: a pilot study. <i>Supportive Care in Cancer</i> , 2020 , 28, 645-652	3.9	10
71	Utilization of an audit tool to evaluate accuracy of treatment summary and survivorship care plans. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 890-898	5.1	2

70	Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24 Suppl 2, S63-S73	4.7	20
69	Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24 Suppl 2, S26-S39	4.7	36
68	Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24 Suppl 2, S6-S12	4.7	20
67	An omega-3 Fatty Acid Enriched Diet Reduces Anxiety-like Behavior While High Dietary Sucrose During Chemotherapy Increases Anxiety-like Behavior in Mice (P14-023-19). <i>Current Developments in Nutrition</i> , 2019 , 3,	0.4	1
66	The Effects of Doxorubicin-based Chemotherapy and Omega-3 Supplementation on Mouse Brain Lipids. <i>Metabolites</i> , 2019 , 9,	5.6	1
65	Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2019 , 25, 6295-6301	12.9	35
64	Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e008777	3.9	9
63	Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. <i>Gait and Posture</i> , 2019 , 71, 62-68	2.6	11
62	Physical Activity After Breast Cancer Surgery: Does Depression Make Exercise Feel More Effortful than It Actually Is?. <i>International Journal of Behavioral Medicine</i> , 2019 , 26, 237-246	2.6	7
61	Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study. <i>Integrative Cancer Therapies</i> , 2019 , 18, 1534735419828823	3.3	16
60	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3495-3507	12.9	21
59	Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement. <i>Phlebology</i> , 2019 , 34, 107-114	2	2
58	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24 Suppl 2, S74-S85	4.7	27
57	Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. <i>Supportive Care in Cancer</i> , 2019 , 27, 3729-3737	3.9	34
56	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019 , 3, 1197-1210	7.8	39
55	An overview of the unique challenges facing African-American breast cancer survivors. <i>Supportive Care in Cancer</i> , 2019 , 27, 729-743	3.9	14
54	Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. <i>American Journal of Cardiology</i> , 2018 , 121, 867-873	3.3	7
53	Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 61-64	2.2	9

52	Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. <i>Cancer Treatment and Research Communications</i> , 2018 , 16, 9-12	2	3
51	An Evaluation of Factors Predicting Diet Quality among Cancer Patients. <i>Nutrients</i> , 2018 , 10,	6.7	4
50	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. <i>Journal of Clinical Investigation</i> , 2018 , 128, 816-825	15.9	38
49	Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. <i>Cancer Medicine</i> , 2018 , 7, 240-253	4.8	17
48	Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018 , 118, 578-588.e1	3.9	19
47	Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 709-718	4.4	16
46	TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. <i>Oncotarget</i> , 2018 , 9, 33459-33470	3.3	44
45	Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy. <i>Nutrients</i> , 2018 , 10,	6.7	9
44	Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices. <i>Breastfeeding Medicine</i> , 2018 , 13, 651-656	2.1	6
43	PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. <i>Breast Journal</i> , 2018 , 24, 911-919	1.2	37
42	A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. <i>Cell Metabolism</i> , 2018 , 28, 118-129.e5	24.6	46
41	Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 69-77	4.4	58
40	Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. <i>Methods in Molecular Biology</i> , 2017 , 1634, 219-234	1.4	1
39	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1437-1447	7.4	44
38	Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12126-e12126	2.2	
37	Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10102-10102	2.2	
36	Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1127-TPS1127	2.2	
35	Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. <i>Experimental and Toxicologic Pathology</i> , 2016 , 68, 505-515		3

34	Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. <i>Gait and Posture</i> , 2016 , 48, 237-242	2.6	22
33	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	14
32	Risk factors for anthracycline-associated cardiotoxicity. <i>Supportive Care in Cancer</i> , 2016 , 24, 2173-2180	3.9	26
31	Effects of exercise interventions during different treatments in breast cancer. <i>Journal of Community and Supportive Oncology</i> , 2016 , 14, 200-9		21
30	Depletion of Normal Cells for CTC Enrichment 2016 , 301-312		
29	Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. <i>Cancer Treatment Communications</i> , 2015 , 3, 28-32		7
28	Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2015 , 402, 51-6	4.4	7
27	Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. <i>Supportive Care in Cancer</i> , 2015 , 23, 2019-24	3.9	15
26	Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. <i>Oncologist</i> , 2015 , 20, 337-43	5.7	35
25	Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 1252-60	2.9	21
24	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 1005-12	3.5	2
23	Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. <i>Journal of Personalized Medicine</i> , 2015 , 5, 50-66	3.6	43
22	Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. <i>Seminars in Oncology Nursing</i> , 2015 , 31, 146-55	3.7	23
21	Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. <i>Oncotarget</i> , 2015 , 6, 20902-20	3.3	75
20	Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 228-34	3	23
19	A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. <i>Investigational New Drugs</i> , 2014 , 32, 1285-94	4.3	12
18	Management options for established chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2014 , 22, 2281-95	3.9	40
17	Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1941-67	2.2	788

16	Treatment-related mortality with everolimus in cancer patients. <i>Oncologist</i> , 2014 , 19, 661-8	5.7	9
15	Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2013 , 21, 2845-51	3.9	16
14	Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. <i>Supportive Care in Cancer</i> , 2013 , 21, 2679-86	3.9	25
13	Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1183-90	3.5	28
12	Human V α V β T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors. <i>International Journal of Cancer</i> , 2013 , 133, 2133-44	7.5	26
11	Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. <i>Supportive Care in Cancer</i> , 2012 , 20, 1991-7	3.9	15
10	Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 49-56	3.5	21
9	Pneumocystis jiroveci Pneumonia in an Atypical Host. <i>Clinical Breast Cancer</i> , 2012 , 12, 138-41	3	9
8	Bone health in adult cancer survivorship. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3665-74	2.2	84
7	Assessment of H2AX levels in circulating tumor cells from patients receiving chemotherapy. <i>Frontiers in Oncology</i> , 2012 , 2, 128	5.3	17
6	Emerging technologies for CTC detection based on depletion of normal cells. <i>Recent Results in Cancer Research</i> , 2012 , 195, 97-110	1.5	53
5	Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. <i>Clinical Breast Cancer</i> , 2011 , 11, 221-7	3	22
4	Epigenetic Therapy in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2011 , 3, 34-43	0.8	37
3	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 713-8	8.9	13
2	Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer. <i>Blood</i> , 2010 , 116, 1739-1739	2.2	
1	Optimal duration of chemotherapy in advanced non-small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2007 , 8, 38-46	5.4	31